Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir—a “knock‐out” is yet to be delivered

Abstract

LINKED CONTENTThis article is linked to Kim et al papers. To view these articles, visit https://doi.org/10.1111/apt.16786 and https://doi.org/10.1111/apt.16920

Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir—A “knock‐out” is yet to be delivered—Authorsʼ reply

“…We appreciate the editorial by Drs Tonthat and Zhou, which highlights the contribution of work on this topic of recent importance 1 . With regard to the use of claims data, we discussed the strengths and limitations of our approach throughout the manuscript 2 .…”

“…Winston Churchill We appreciate the editorial by Drs Tonthat and Zhou, which highlights the contribution of work on this topic of recent importance. 1 With regard to the use of claims data, we discussed the strengths and limitations of our approach throughout the manuscript. 2 While they do not include laboratory results that can inform analyses in hospital-based clinical cohorts, they do provide the opportunity to look at a larger and more heterogeneous population than clinical cohorts that should yield more broadly generalizable results and greater power to observe effects.…”